KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Receivables (2016 - 2024)

Palvella Therapeutics has reported Receivables over the past 9 years, most recently at $10.6 million for Q4 2022.

  • Quarterly Receivables rose 219.38% to $10.6 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $10.6 million through Dec 2022, up 219.38% year-over-year, with the annual reading at $10.6 million for FY2022, 219.38% up from the prior year.
  • Receivables was $10.6 million for Q4 2022 at Palvella Therapeutics, up from $829000.0 in the prior quarter.
  • Over five years, Receivables peaked at $17.0 million in Q2 2021 and troughed at $829000.0 in Q3 2022.
  • The 5-year median for Receivables is $6.1 million (2018), against an average of $6.6 million.
  • Year-over-year, Receivables soared 8381.79% in 2018 and then tumbled 95.12% in 2022.
  • A 5-year view of Receivables shows it stood at $2.7 million in 2018, then soared by 162.38% to $7.1 million in 2019, then crashed by 75.93% to $1.7 million in 2020, then soared by 94.2% to $3.3 million in 2021, then skyrocketed by 219.38% to $10.6 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Receivables are $10.6 million (Q4 2022), $829000.0 (Q3 2022), and $1.3 million (Q2 2022).